Global Arthritis Monoclonal Antibodies Market

Orthrobiologic devices are implants composed of cells and proteins that are naturally found in the human body and that provide accelerated healing by stimulating efficient regrowth of musculoskeletal tissues, including bones, cartilage, tendons, and ligaments. The main product types of orthobiologics devices and equipment are demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and synthetic orthobiologics. Stem cell therapy is promoting the repair response of diseased, dysfunctional, or injured tissue using stem cells or their derivatives. The various applications involved are osteoarthritis and degenerative arthritis, soft-tissue injuries, fracture recovery, maxillofacial and dental applications, spinal fusion, trauma repair, and reconstructive surgery that are used by various end-users such as hospitals, orthopedic clinics, and others. The orthobiologics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides orthobiologics devices and equipment market statistics, including orthobiologics devices and equipment industry global market size, regional shares, competitors with a orthobiologics devices and equipment market share, detailed orthobiologics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the orthobiologics devices and equipment industry. This orthobiologics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global othobiologics devices and equipment market grew from $4.86 billion in 2022 to $5.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The othobiologics devices and equipment market is expected to grow from $6.85 billion in 2027 at a CAGR of 6.7%. The aging population profile of most countries contributed to the growth of orthobiologics devices and equipment market globally. According to the United Nations report, there were 962 million people aged over 60 across the globe, comprising 13% of the global population. The population aged over 60 is expected to grow at a rate of about 3% every year. The report further estimated that Europe had the highest percentage of the population aged over 60. The number of people globally over the age of 65 grew by 33%, according to estimates based on Population Reference Bureau data. The increase in the aging population has increased the patient pool of many orthopedic disorders and led to an increase in the demand for orthobiologics devices and equipment market. Rising incidences of post-surgical complications in patients implanted with orthobiologics devices are one of the major restraints in the orthobiologics devices and equipment market. Surgical procedures with orthobiologics grafts, implants, and devices have become increasingly common in recent years. Major postoperative complications include device failures, bleeding, postoperative infections, immune responses, and rejections. These procedures may develop post-surgery complications which refer to the development of any unwanted or unexpected conditions related to the device, graft, or implant. These complications may vary with the type of procedure, implant, graft, or device, the experience of the surgeon, improper device testing procedures before market launch, device location in the body, and the health and biological response of the individual. The increasing post-operative complications and device failures can limit the orthobiologics devices and equipment market. Biodegradable implants are increasingly being used in orthobiologics treatment and trauma orthopedic surgeries. Biodegradable implants are used to replace a missing biological structure, support a damaged biological structure, and enhance the existing bone structure. Biodegradable products such as re-absorbable polymers composed of polyglycolic acid and polylactic acid manufactured in the form of plates, screws, and pins are replacing traditional devices like plates and screws which are more expensive. Surgeons are preferring biodegradable implants to replace conventional implants, as biodegradable implants can be engineered to provide temporary support for bone fractures, can degrade at a rate matching new tissue formation, eliminate the need for the second surgery, and are highly useful in fracture fixation in children with less implant-related infections. For instance, Stryker Corp. offers orthobiologics such as bone repair biodegradable products that are used in bone regeneration and bone healing, soft tissue regeneration, and muscle connection to bone Regulatory changes are likely to lead to increased costs relating to new product development and supply of orthobiologics devices. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. In November 2017, the USFDA has announced a comprehensive regenerative medicine policy framework to facilitate innovation. This policy deals with the manufacture of tissues, human cells, and cellular and tissue-based products other procedures to prevent the introduction, transmission, and spread of communicable diseases. Orthobiologics such as stem cell therapies are approved through this framework. The potential loss of revenue due to delays in product release, additional costs incurred by the time-consuming approval processes, and changing regulations puts a strain on investments relating to orthobiologics devices development. Major players in the orthobiologics devices and equipment market are Medtronic, Arthrex Inc., DePuy Synthes (A Subsidiary of Johnson & Johnson), Stryker Corporation, Zimmer Biomet, Bioventus LLC., Baxter International Inc., Integra Lifesciences Holding Corporation, Nuvasive Inc., and Sanofi. North America was the largest region in the global orthobiologics devices and equipment market in 2022. Western Europe was the second-largest region in the orthobiologics devices and equipment market. The regions covered in global orthobiologics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The counties covered in the orthobiologics devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The orthrobiologic devices market consists of sales of demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and other synthetic orthobiologics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global orthobiologics devices and equipment market is segmented - 1) By Product Type: Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cell Therapy, Plasma-Rich Protein, Viscosupplementation, Bone Morphogenetic Protein, Synthetic Orthobiologics 2) By Application: Osteoarthritis and Degenerative Arthritis, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications, Spinal Fusion, Trauma Repair, Reconstructive Surgery 3) By End Use: Hospitals, Orthopedic Clinics, Other End Users

Microbiome refers to a group of microbes that live in a certain habitat and include fungi, bacteria, and viruses. It is all of the bacteria, fungi, protozoa, and viruses' genetic material that dwells on and within the human body. The microbiome's bacteria also aid in digestion, immune system control, defence against disease-causing bacteria, and the production of vitamins like Vitamin K, which is required for blood clotting, and the B vitamins B12, thiamine, and riboflavin. The main types of microbiomes are faecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation or stool transplantation. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and others. The microbiome market research report is one of a series of new reports from The Business Research Company that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global microbiome market size will grow from $0.39 billion in 2022 to $0.57 billion in 2023 at a compound annual growth rate (CAGR) of 45.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiome market size is expected to grow from $1.09 billion in 2027 at a CAGR of 17.6%. The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn's disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as having potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. For instance, in September 2020, according to the National Institute of Health, a US-based biomedical and public health research agency, between 600,000 and 900,000 Americans may suffer from ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market. The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market. The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotic for both females and males. The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier, and oxidative stress. In January 2021, Novozymes, a Denmark-based biotechnology company, acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a probiotics company based in the United States. Major players in the microbiome market are MicroBiome Therapeutics LLC., Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc., AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc., and ViThera Pharmaceuticals Inc. North America was the largest region in the microbiome market in 2022. The regions covered in the global microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global microbiome market is segmented - 1) By Type: Fecal Microbiota Transplantation (FMT), Microbiome Drugs 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Other Applications 3) By Technology: Genomics, Proteomics, and Metabolomics

Psoriatic arthritis treatment refers to a method of treatment or drug used to stop or lessen a chronic inflammatory disease of the joints and the areas where tendons and ligaments attach to the bones (entheses). This treatment focuses on controlling skin involvement and treating joint pain and disability. The main classes of drugs in psoriatic arthritis treatment are nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and others. A biologic medicine (biologics) is a substance that is made from or contains living organism components.The different routes of administration include oral, parenteral, and topical, and they are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The psoriatic arthritis treatment market research report is one of a series of new reports from The Business Research Company that provides psoriatic arthritis treatment market statistics, including global market size, regional shares, competitors with a psoriatic arthritis treatment market share, detailed psoriatic arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the psoriatic arthritis treatment industry. This psoriatic arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global psoriatic arthritis treatment market grew from $8.92 billion in 2022 to $9.94 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psoriatic arthritis treatment market is expected to grow from $14.36 billion in 2027 at a CAGR of 9.6%. The rise in the prevalence of psoriasis and psoriatic arthritis boosted the growth of the psoriatic arthritis treatment market. Psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory disorders that can severely impair health and quality of life. Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30% in psoriatic patients. For instance, in June 2021, according to the National Psoriasis Foundation, a US-based healthcare agency, more than 8 million people in the United States and 125 million people worldwide suffered from psoriasis, a chronic immune-mediated illness. Furthermore, in the USA, about 30% of people with psoriasis also develop psoriatic arthritis. Thus, an increase in the prevalence of psoriasis and psoriatic arthritis drives market growth. The development of novel drugs such as Janus kinase (JAK) inhibitors for treating psoriatic arthritis is shaping the market. Janus kinase (JAK) inhibitors are orally administered small molecules that are emerging as a novel treatment for psoriatic arthritis patients. There are three JAK inhibitors approved for the treatment of autoimmune diseases: tofacitinib, baricitinib, and upadacitinib. Among them, Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR are the first Janus kinase (JAK) inhibitors that have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They are used to treat adult patients with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). In June 2020, AbbVie, a leading US-based pharmaceutical company, announced that it had applied for the approval of upadacitinib (RINVOQ), a JAK inhibitor, with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Amgen Inc., an American biopharmaceutical company headquartered in Thousand Oaks, California, acquired Celgene’s Otezla for $13.4 billion. Otezla supports Amgen’s mission to bring innovative medicines to patients and expand its product portfolio. Amgen also gets worldwide rights with Otezla's acquisition. Otezla (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis and active psoriatic arthritis. Celgene Corporation is a US-based biopharmaceutical company, acquired by Bristol-Myers Squibb Company, that develops and markets drugs used in the treatment of cancer and anti-inflammatory diseases. Major players in the psoriatic arthritis treatment market are AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, Pfizer, UCB Biosciences Inc., and Hoffmann La Roche Ltd. North America was the largest region in the psoriatic arthritis treatment market in 2022. The regions covered in the global psoriatic arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The psoriatic arthritis treatment market includes revenues earned by entities by reducing pain and swelling and controlling inflammation and pain. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global psoriatic arthritis treatment market is segmented - 1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes 2) By Route Of Administration: Oral, Parenteral, Topical 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

TNF alpha inhibitors refer to medications that are used to treat inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis and that help to reduce or eliminate inflammation. TNF inhibitors may increase the risk of skin cancer, particularly non-melanoma skin cancers like squamous cell carcinoma. The main types of drugs in TNF alpha inhibitors are remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), and simponi (golimumab). Remicade is a prescription medication for people with moderately to severely active Crohn's disease who haven't responded to other treatments.The different routes of administration include oral, subcutaneous, intravenous, and others and involve various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and others. The TNF alpha inhibitors market research report is one of a series of new reports from The Business Research Company that provides TNF alpha inhibitors market statistics, including global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global tnf alpha inhibitors market grew from $40.73 billion in 2022 to $42.2 billion in 2023 at a compound annual growth rate (CAGR) of 3.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tnf alpha inhibitors market is expected to grow from $44.95 billion in 2027 at a CAGR of 1.6%. The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitor market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology, and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases of ulcerative colitis per 100,000 person-years and 0.1-16 cases of Crohn's disease per 100,000 person-years, and overall, the IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors, contributing to the growth of the market. The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitor market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. According to the Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, or viral, leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market. The companies in the market are focusing on research and development for TNF alpha inhibitors. The focus on research and development activities allows companies in the market to evaluate and accept high-quality research proposals from all over the world and provide biologically and clinically superior performance with a more comfortable patient experience and faster recovery times. For example, in February 2022, MyMD Pharmaceuticals, Inc., a US based clinical stage pharmaceutical company committed to extending healthy lifespan, announced Phase 1 clinical trial data demonstrating MYMD-1’s reduction of tumor necrosis factor-alpha (TNF-a), the molecules that are the root cause of aging, in the blood of healthy human subjects. MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-a), a driver of chronic inflammation. AbbVie Inc., a biopharmaceutical company based in the United States, completed the $63 billion acquisition of Allergan plc in May 2020.The acquisition is expected to expand and diversify AbbVie Inc.’s revenue base and its existing immunology portfolio. Allergan plc is an Ireland-based pharmaceutical company engaged in manufacturing and marketing drugs and medical devices in the areas of the central nervous system, eye care, medical aesthetics, and gastroenterology. Major players in the TNF alpha inhibitor market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Merck & Co. Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals North America was the largest region in the TNF alpha inhibitors market in 2022. The regions covered in the global TNF alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the TNF alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global TNF alpha inhibitors market is segmented - 1) By Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab) 2) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Route Of Administration 3) By Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types

Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system. The main types of interleukin inhibitors are IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The interleukin inhibitors market research report is one of a series of new reports from The Business Research Company that provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with an interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global interleukin inhibitors market grew from $31.73 billion in 2022 to $36.96 billion in 2023 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interleukin inhibitors market is expected to grow from $68.56 billion in 2027 at a CAGR of 16.7%. An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitor market. Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses to prevent damage to the host, and maintain normal tissue homeostasis. There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval. High costs associated with biological therapy are hampering the interleukin inhibitor market. The biologic treatment that has revolutionised the care of psoriasis patients is more expensive than the other treatments. The total annual cost ranged from $2,077 to $13,132 in the US for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient. As of 2020, biologics treatment costs were around $10,000 to $30,000 per year. The higher price of biologics and low healthcare expenditure in developing countries are therefore likely to hinder market growth. The patent expiration of biologic drugs creates opportunities for biosimilar drugs, which are a less expensive alternative.Major companies in the interleukin sector are focusing on developing biosimilars for interleukin inhibitors. For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), among others, are in development by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biological therapy, and access to treatment may be limited for several reasons, including higher treatment costs. This factor, coupled with rapid advances in biotechnology and analytical sciences that ensure comparability of biosimilars to biological drugs, drives the trend for biosimilars. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals. North America was the largest region in the interleukin inhibitors market in 2022. The regions covered in the global interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global interleukin inhibitors market is segmented - 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Pre-filled syringes are syringes that are supplied with the substance to-be injected already in the injection. These syringes are used to accurately delivering the contents in the desired location. The main types of prefilled syringes are conventional prefilled syringes and safety prefilled syringes. Conventional prefilled syringes contain a single-dose packet of vaccines, with a needle fixed by the manufacturer. The needle is for one time use, and the syringe is disposed of after application. Safety prefilled syringes contain a single-dose packet of vaccine, which is self-administrated by patients requiring regular injections in a home setting.  The needles are manufactured using glass and plastic with single-chamber prefilled syringes, dual-chamber prefilled syringes and customised prefilled syringes. These prefilled syringes are used for diabetes, rheumatoid arthritis, anaphylaxis, cancer, thrombosis, ophthalmology, and others. The pre-filled syringes market research report is one of a series of new reports from The Business Research Company that provides pre-filled syringes market statistics, including pre-filled syringes industry global market size, regional shares, competitors with a pre-filled syringes market share, detailed pre-filled syringes market segments, market trends and opportunities, and any further data you may need to thrive in the pre-filled syringes industry. The pre-filled syringe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pre filled syringes market size grew from $6.39 billion in 2022 to $7.29 billion in 2023 at a compound annual growth rate (CAGR) of 14.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pre filled syringes market size is expected to grow to $12.19 billion in 2027 at a CAGR of 13.7%. The high demand for pre-filled syringes to administer COVID-19 vaccines is expected to boost the pre-filled syringes market during the forecast period. Pre-filled syringes are preferred for administering COVID-19 vaccines to reduce the risk for needle stick infections. To cater to the growing demand for administering COVID-19 vaccines, the companies are focusing on increasing the production of pre-filled syringes. For instance, in May 2020, the US Department of Defense awarded a contract of $138 million with ApiJect Systems America for "Project Jumpstart" and "RAPID USA" to facilitate pre-filled production syringes for the COVID-19 vaccine. Project Jumpstart supported the supply chain for prefilled syringes that manufacture 100 million prefilled syringes. The contract also accelerated the launch of RAPID USA to facilitate the production of 500 million pre-filled syringes by 2021. Thus, the high demand for pre-filled syringes to administer COVID-19 vaccines is expected to fuel the market growth during the forecast period. Product recalls attributed to factors such as breakages, leachability, defects in packaging, and contamination hindered the pre-filled syringes market's growth in the historic period. A product recall is a process of retrieving or replacing the products already in the market, wherein the company bears the cost of replacing and fixing defective products or reimbursing affected consumers. Product recalls and affecting a market substantially as they can affect the company's performance within the market, change its financial profile, and negatively impact its reputation. For instance in 2021, according to the American Hospital Association, a US-based a health care industry trade group, an estimated 267 million prefilled saline syringes were recalled by Cardinal Health due to the risk that the plunger could reintroduce air into the syringe and result in major negative effects. Therefore, the product recalls due to various factors in the manufacturing process or packaging restrained the growth of the market in the historic period. Companies in the prefilled syringes market are increasingly investing in connected prefilled syringes, which allows healthcare professionals to track and access data. A connected pre-filled syringe is a drug delivery device that can be connected to a smartphone that tracks data and reports to healthcare professionals accordingly. In 2020, Biocorp launched Injay, a connected pre-filled syringe based on NFC technology wherein the technology helps transfer data to a smartphone or specific transmitters, depending on specific use cases and environment. Major players in the prefilled syringes market are Becton Dickinson and Company, Gerresheimer AG, Schott Group, West Pharmaceutical Services Inc., Baxter International Inc., Nipro Corporation, Terumo Corporation, Vetter Pharma International GmbH, Stevanato Group, Weigao Group, Novartis, Catalent Inc., Unilife Corporation, Eli Lilly and Company, Amgen, Bayer AG, Pfizer Inc., Bristol-Myers Squibb Company, F. Hoffman-La Roche AG, AbbVie Inc., Owen Mumford, AptarGroup Inc., Medtronic, Abbott, Fresenius Kabi, Medpro, Mylan, Elcam Medical, YPSOMED, Oval Medical Technologies, and SHL Medical AG. Europe was the largest region in the prefilled syringes market in 2022. The regions covered in the prefilled syringes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pre-filled syringes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pre-filled syringes market consists of sales of glass prefilled syringes and plastic prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pre filled syringes market is segmented - 1) By Type: Conventional Prefilled Syringes, Safety Prefilled Syringes 2) By Material: Glass Prefilled Syringes, Plastic Prefilled Syringes 3) By Design: Single-Chamber Prefilled Syringes, Dual- Chamber Prefilled Syringes, Customized Prefilled Syringes 4) By Application: Diabetes, Rheumatoid Arthritis, Anaphylaxis, Cancer, Thrombosis, Ophthalmology, Other Applications

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The main types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs. A muscle relaxant is a medication that causes muscle contractions to cease. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global musculoskeletal disorders drugs market size is expected to grow from $897.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The musculoskeletal disorders drugs market is expected to reach $163.94 billion in 2026 at a CAGR of 12%. The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market. Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders. Major companies in the musculoskeletal disorders drugs market include Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd, Biogen Inc and Sino Biopharmaceutical. North America was the largest region in the musculoskeletal disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global musculoskeletal disorders drugs market is segmented - 1) By Type: Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The microbiome therapeutics market consists of sales of microbiome therapeutics and related services by entities (organizations, sole traders, partnership) which are used to treat and prevent various diseases. The microbiome comprises the genetic material within a microbiota which is an entire collection of microorganisms found in and on all multicellular organisms. The main products of microbiome therapeutics are probiotics, prebiotics, symbiotics, and other products. Probiotics are a combination of live beneficial bacteria and/or yeasts that naturally live in the body. The various distribution channels involved are hospital pharmacies, drug stores, retail pharmacies, and e-commerce stores. The applications included are inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and other applications. The global microbiome therapeutics market size is expected to grow from $0.29 billion in 2021 to $0.39 billion in 2022 at a compound annual growth rate (CAGR) of 34.7%. The global microbiome therapeutics market size is expected to grow to $1 billion in 2026 at a compound annual growth rate (CAGR) of 26.4%. The rising prevalence of obesity is expected to propel the growth of the microbiome therapeutics market. Sedentary lifestyles, busy work lives, and unhealthy food choices are gradually becoming the leading causes of obesity globally. Growing urbanization and busy lifestyles are leading to an increasing preference for packaged and processed foods and physical inactivity. Microbiome therapeutics help prevent and treat diabetes by regulating sugar levels. For instance, in 2022, according to the UK Parliament, a survey found that men are more likely than women to be overweight or obese (68.2% of men, 60.4% of women). People aged 45–74 are most likely to be overweight or obese. Therefore, the rising prevalence of obesity is driving the growth of microbiome therapeutics. Increased research and development is a key trend gaining popularity in the microbiome therapeutics market. Companies operating in the microbiome therapeutics market are focused on developing new innovations to increase their market share. For instance, in March 2022, Microbiotica, a UK-based company, raised $67 million in a Series B round to push two microbiome-based lead assets through phase 1b trials, slated to start this year. In April 2022, Xbiome Inc., a China-based artificial intelligence microbiome therapeutics startup, acquired a clinical-stage M201 program from Assembly Biosciences, Inc. for an undisclosed amount. This acquisition reflects Xbiome’s commitment as one of the leaders in the rising field of microbiome therapeutics. Assembly Biosciences, Inc. is a US-based clinical-stage biotechnology company. Major players in the microbiome therapeutics market are Seres Therapeutics, Enterome Bioscience, Rebiotix, Microbiome Therapeutics, and Ritter Pharmaceuticals. North America was the largest region in the microbiome therapeutics market in 2021. The regions covered in the global microbiome therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microbiome therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global microbiome therapeutics market is segmented - 1) By Product: Probiotics, Prebiotics, Symbiotics, and Others 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and Others 3) By Distribution Channel: Hospital Pharmacies, Drug stores, Retail Pharmacies, and E-commerce stores